Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Research Report 2022

Publisher Name :
Date: 10-Aug-2022
No. of pages: 99
Inquire Before Buying

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

- First Generation ALK Inhibitor

- Second Generation ALK Inhibitor

- Third Generation ALK Inhibitor

Segment by Application

- Hospital Pharmacy

- Retail Pharmacy

- Others

By Region

- North America

- - United States

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - China Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

By Company

- Astellas Pharma

- AstraZeneca

- Betta Pharmaceuticals

- GlaxoSmithKline

- Merck

- Novartis

- Pfizer

- Roche

- Takeda Pharmaceuticals

- Turning Point Therapeutics

Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Research Report 2022

Table of Contents
1 Anaplastic Lymphoma Kinase ALK Inhibitor Market Overview
1.1 Product Overview and Scope of Anaplastic Lymphoma Kinase ALK Inhibitor
1.2 Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Type
1.2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 First Generation ALK Inhibitor
1.2.3 Second Generation ALK Inhibitor
1.2.4 Third Generation ALK Inhibitor
1.3 Anaplastic Lymphoma Kinase ALK Inhibitor Segment by Application
1.3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Comparison by Application: (2022-2028)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue 2017-2028
1.4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales 2017-2028
1.4.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Region: 2017 Versus 2021 Versus 2028
2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Competition by Manufacturers
2.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturers (2017-2022)
2.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturing Sites, Area Served, Product Type
2.5 Anaplastic Lymphoma Kinase ALK Inhibitor Market Competitive Situation and Trends
2.5.1 Anaplastic Lymphoma Kinase ALK Inhibitor Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Anaplastic Lymphoma Kinase ALK Inhibitor Players Market Share by Revenue
2.5.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario by Region
3.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
3.3.1 North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country
3.3.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
3.4.1 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country
3.4.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Region
3.5.1 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region
3.5.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
3.6.1 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country
3.6.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Market Facts & Figures by Country
3.7.1 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country
3.7.2 Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Analysis by Type
4.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2017-2022)
4.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Type (2017-2022)
4.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2017-2022)
5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Historic Market Analysis by Application
5.1 Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2017-2022)
5.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Application (2017-2022)
5.3 Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Astellas Pharma
6.1.1 Astellas Pharma Corporation Information
6.1.2 Astellas Pharma Description and Business Overview
6.1.3 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.1.5 Astellas Pharma Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.2.4 AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Betta Pharmaceuticals
6.3.1 Betta Pharmaceuticals Corporation Information
6.3.2 Betta Pharmaceuticals Description and Business Overview
6.3.3 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.3.5 Betta Pharmaceuticals Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.4.4 GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Roche
6.8.1 Roche Corporation Information
6.8.2 Roche Description and Business Overview
6.8.3 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.8.5 Roche Recent Developments/Updates
6.9 Takeda Pharmaceuticals
6.9.1 Takeda Pharmaceuticals Corporation Information
6.9.2 Takeda Pharmaceuticals Description and Business Overview
6.9.3 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.9.5 Takeda Pharmaceuticals Recent Developments/Updates
6.10 Turning Point Therapeutics
6.10.1 Turning Point Therapeutics Corporation Information
6.10.2 Turning Point Therapeutics Description and Business Overview
6.10.3 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product Portfolio
6.10.5 Turning Point Therapeutics Recent Developments/Updates
7 Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturing Cost Analysis
7.1 Anaplastic Lymphoma Kinase ALK Inhibitor Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Anaplastic Lymphoma Kinase ALK Inhibitor
7.4 Anaplastic Lymphoma Kinase ALK Inhibitor Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Anaplastic Lymphoma Kinase ALK Inhibitor Distributors List
8.3 Anaplastic Lymphoma Kinase ALK Inhibitor Customers
9 Anaplastic Lymphoma Kinase ALK Inhibitor Market Dynamics
9.1 Anaplastic Lymphoma Kinase ALK Inhibitor Industry Trends
9.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
9.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market Challenges
9.4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints
10 Global Market Forecast
10.1 Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Anaplastic Lymphoma Kinase ALK Inhibitor by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Anaplastic Lymphoma Kinase ALK Inhibitor by Type (2023-2028)
10.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Anaplastic Lymphoma Kinase ALK Inhibitor by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Anaplastic Lymphoma Kinase ALK Inhibitor by Application (2023-2028)
10.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Anaplastic Lymphoma Kinase ALK Inhibitor by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Anaplastic Lymphoma Kinase ALK Inhibitor by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Competitive Situation by Manufacturers in 2021
Table 5. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Anaplastic Lymphoma Kinase ALK Inhibitor Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Anaplastic Lymphoma Kinase ALK Inhibitor Manufacturing Sites and Area Served
Table 11. Manufacturers Anaplastic Lymphoma Kinase ALK Inhibitor Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Anaplastic Lymphoma Kinase ALK Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anaplastic Lymphoma Kinase ALK Inhibitor as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2017-2022) & (K Units)
Table 16. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2017-2022)
Table 17. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2017-2022)
Table 19. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2017-2022) & (K Units)
Table 20. North America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2017-2022)
Table 21. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2017-2022)
Table 23. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2017-2022) & (K Units)
Table 24. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2017-2022)
Table 25. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2017-2022)
Table 31. Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2017-2022)
Table 33. Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Country (2017-2022)
Table 39. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales by Type (2017-2022) & (K Units)
Table 40. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Type (2017-2022)
Table 41. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Type (2017-2022)
Table 43. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units) by Application (2017-2022)
Table 45. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Application (2017-2022)
Table 46. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Application (2017-2022)
Table 48. Global Anaplastic Lymphoma Kinase ALK Inhibitor Price by Application (2017-2022) & (US$/Unit)
Table 49. Astellas Pharma Corporation Information
Table 50. Astellas Pharma Description and Business Overview
Table 51. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Astellas Pharma Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 53. Astellas Pharma Recent Developments/Updates
Table 54. AstraZeneca Corporation Information
Table 55. AstraZeneca Description and Business Overview
Table 56. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. AstraZeneca Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 58. AstraZeneca Recent Developments/Updates
Table 59. Betta Pharmaceuticals Corporation Information
Table 60. Betta Pharmaceuticals Description and Business Overview
Table 61. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Betta Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 63. Betta Pharmaceuticals Recent Developments/Updates
Table 64. GlaxoSmithKline Corporation Information
Table 65. GlaxoSmithKline Description and Business Overview
Table 66. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. GlaxoSmithKline Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 68. GlaxoSmithKline Recent Developments/Updates
Table 69. Merck Corporation Information
Table 70. Merck Description and Business Overview
Table 71. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Merck Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 73. Merck Recent Developments/Updates
Table 74. Novartis Corporation Information
Table 75. Novartis Description and Business Overview
Table 76. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Novartis Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 78. Novartis Recent Developments/Updates
Table 79. Pfizer Corporation Information
Table 80. Pfizer Description and Business Overview
Table 81. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Pfizer Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 83. Pfizer Recent Developments/Updates
Table 84. Roche Corporation Information
Table 85. Roche Description and Business Overview
Table 86. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Roche Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 88. Roche Recent Developments/Updates
Table 89. Takeda Pharmaceuticals Corporation Information
Table 90. Takeda Pharmaceuticals Description and Business Overview
Table 91. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Takeda Pharmaceuticals Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 93. Takeda Pharmaceuticals Recent Developments/Updates
Table 94. Turning Point Therapeutics Corporation Information
Table 95. Turning Point Therapeutics Description and Business Overview
Table 96. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Turning Point Therapeutics Anaplastic Lymphoma Kinase ALK Inhibitor Product
Table 98. Turning Point Therapeutics Recent Developments/Updates
Table 99. Production Base and Market Concentration Rate of Raw Material
Table 100. Key Suppliers of Raw Materials
Table 101. Anaplastic Lymphoma Kinase ALK Inhibitor Distributors List
Table 102. Anaplastic Lymphoma Kinase ALK Inhibitor Customers List
Table 103. Anaplastic Lymphoma Kinase ALK Inhibitor Market Trends
Table 104. Anaplastic Lymphoma Kinase ALK Inhibitor Market Drivers
Table 105. Anaplastic Lymphoma Kinase ALK Inhibitor Market Challenges
Table 106. Anaplastic Lymphoma Kinase ALK Inhibitor Market Restraints
Table 107. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Type (2023-2028) & (K Units)
Table 108. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share Forecast by Type (2023-2028)
Table 109. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 110. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share Forecast by Type (2023-2028)
Table 111. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Application (2023-2028) & (K Units)
Table 112. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share Forecast by Application (2023-2028)
Table 113. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 114. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share Forecast by Application (2023-2028)
Table 115. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Forecast by Region (2023-2028) & (K Units)
Table 116. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share Forecast by Region (2023-2028)
Table 117. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 118. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share Forecast by Region (2023-2028)
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anaplastic Lymphoma Kinase ALK Inhibitor
Figure 2. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Type in 2021 & 2028
Figure 3. First Generation ALK Inhibitor Product Picture
Figure 4. Second Generation ALK Inhibitor Product Picture
Figure 5. Third Generation ALK Inhibitor Product Picture
Figure 6. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Application in 2021 & 2028
Figure 7. Hospital Pharmacy
Figure 8. Retail Pharmacy
Figure 9. Others
Figure 10. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size (2017-2028) & (US$ Million)
Figure 12. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales (2017-2028) & (K Units)
Figure 13. Anaplastic Lymphoma Kinase ALK Inhibitor Sales Share by Manufacturers in 2021
Figure 14. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Anaplastic Lymphoma Kinase ALK Inhibitor Players: Market Share by Revenue in 2021
Figure 16. Anaplastic Lymphoma Kinase ALK Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region (2017-2022)
Figure 18. Global Anaplastic Lymphoma Kinase ALK Inhibitor Sales Market Share by Region in 2021
Figure 19. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region (2017-2022)
Figure 20. Global Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Market Share by Region in 2021
Figure 21. United States Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Turkey Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Saudi Arabia Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. UAE Anaplastic Lymphoma Kinase ALK Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Sales Market Share of Anaplastic Lymphoma Kinase ALK Inhibitor by Type (2017-2022)
Figure 44. Manufacturing Cost Structure of Anaplastic Lymphoma Kinase ALK Inhibitor
Figure 45. Manufacturing Process Analysis of Anaplastic Lymphoma Kinase ALK Inhibitor
Figure 46. Anaplastic Lymphoma Kinase ALK Inhibitor Industrial Chain Analysis
Figure 47. Channels of Distribution
Figure 48. Distributors Profiles
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs